CLINICAL TRIALS PROFILE FOR RITONAVIR

505(b)(2) Clinical Trials for RITONAVIR

This table shows clinical trials for potential 505(b)(2) applications. See the next table for all clinical trials

Trial Type	Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
New Combination	NCT00196625 ↗	Salvage Therapy With Amprenavir, Lopinavir and Ritonavir in HIV-Infected Patients in Virological Failure.	Completed	French National Agency for Research on AIDS and Viral Hepatitis	Phase 2	2000-11-01	HIV infected patients are treated with highly active antiretroviral therapy (HAART). Side effects and the great number of pills reduces adherence to the treatment, and induces therapeutic failure. In order to maintain efficacy of HAART, new combination is evaluated. The aim of the study is to compare the antiviral efficacy of this salvage therapy combining lopinavir and amprenavir with 200 mg/d or 400 mg/d ritonavir, together with nucleoside reverse transcriptase inhibitors, over a 26-week period in HIV-infected patients in whom multiple antiretroviral regimens had failed.
New Formulation	NCT01052883 ↗	TMC114-TiDP3-C182 - A Study to Compare the Oral Bioavailability of a 800 mg Prototype Tablet Formulation of Darunivar (DRV) to That of the 400 mg Commercial Tablet Formulation in the Presence of Low Dose Ritonavir, Under Fasted and Fed Conditions	Completed	Tibotec Pharmaceuticals, Ireland	Phase 1	2010-03-01	The purpose of this study is to compare the drug levels of darunavir obtained after administration of a single administration of the 800 mg tablet (new formulation) to that following administration of two 400 mg commercial tablets formulation when administered under fed and fasted conditions to those also taking low-dose ritonavir. Darunavir is marketed for the treatment of HIV. The short-term safety and tolerability of darunavir following administration of a single 800 mg dose of darunavir given to healthy volunteers taking taking low-dose ritonavir will also be assessed.
New Formulation	NCT02244190 ↗	Bioequivalence of Two Different Oral Solutions Tipranavir Administered in Combination With Ritonavir to Healthy Volunteers	Completed	Boehringer Ingelheim	Phase 1	2008-04-01	To establish the bioequivalence of the new tipranavir oral solution formulation with the current tipranavir oral solution formulation following single-dose administration. In each case, 500 mg tipranavir was coadministered with 200 mg ritonavir.
New Dosage	NCT02435563 ↗	Dose Adaptation to Offset the Interaction Between Ticagrelor and Ritonavir by Population-based PK Modeling	Completed	University Hospital, Geneva	Phase 2	2014-08-01	Ticagrelor is a new generation antiplatelet agent with higher efficacy as compared to clopidogrel and prasugrel in treatment of patients with moderate and high ischemic risks. Ticagrelor is active as such and its hepatic metabolism by CYP3A generates also an active metabolite. Because of the remarkable progress in HIV therapies the number of older age patients is on the rise, requiring adequate cardiovascular treatment. Since frontline HIV therapies include ritonavir, a strong inhibitor of CYP3A enzyme, ticagrelor is contraindicated in these patients because of the expected interaction and bleeding risk. A lower efficacy of clopidogrel and prasugrel, which are both pro-drugs, in the presence of ritonavir has been already demonstrated. Therefore, administration of a lower dose of ticagrelor may be a good alternative in HIV patients in order to lessen the impact of this pharmacokinetic interaction. The aim of this study is to adjust the dose of ticagrelor in case of co-treatment with ritonavir to achieve the same pharmacokinetic profile as administered alone using a physiologically-based pharmacokinetic (PBPK) model. As the first step, a pharmacokinetic (PK) model for ticagrelor and its active metabolite will be created based on available in vitro and in vivo parameters in healthy volunteers. An open-label, 2 sessions cross over study will be conducted with 20 healthy male volunteers at Clinical Research Center (CRC) of Geneva University Hospitals (HUG). During the first session of the clinical trial, a single dose 180 mg ticagrelor will be administered to the volunteers and obtained pharmacokinetic data will be fitted into the model for optimization. Thereafter a simulated trial by the Simcyp® simulator in presence of a single dose 100 mg ritonavir will allow evaluating the impact of CYP3A inhibition on the concentration-time profile of ticagrelor and its active metabolite. The necessary dose of ticagrelor to minimize the magnitude of this interaction will be calculated. This new dose will be co-administered with ritonavir in the same volunteers during the second session of the clinical trial. The purpose is to obtain the same PK profile with single dose of 180 mg ticagrelor administered alone and with an adapted dose of ticagrelor co-administered with a single dose 100 mg ritonavir. Moreover, the pharmacodynamic effect of ticagrelor will be measured in both sessions of the clinical trial using two specific platelet function tests: the VAsodilator-Stimulated Phosphoprotein assay (VASP) and VerifyNow® P2Y12. With the same PK profile, the same pharmacodynamic activity is expected. The modulation of activity of CYP3A and P-gp by ritonavir will be also monitored using micro dose midazolam and fexofenadine as probe substrates. The purpose of this study is to use the Simcyp® Simulator mechanistic PBPK modeling to broaden the application field of ticagrelor, especially in HIV patients. Since PK models are often created after clinical observations, the prospective aspect of this study is of particular value as the model will be first created and then applied to an unknown clinical scenario.
New Formulation	NCT06139796 ↗	Pharmacokinetics Safety and Acceptability of DRV/r for Children Living With HIV	Not yet recruiting	AMS-PHPT Research Collaboration	Phase 1/Phase 2	2024-06-01	The UNIVERSAL2 study is a research project designed to evaluate a newly developed formulation of an approved drug for children living with HIV aged over 3 years and weighing between 10 and 25 kg. The aim of UNIVERSAL2 is to determine the right dosage of this new formulation.

All Clinical Trials for RITONAVIR

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00000822 ↗	A Phase I/II Double-Blind Controlled Trial to Determine the Safety and Immunogenicity of HIV-1 MN rgp160 Immuno AG Vaccine Therapy in HIV-Infected Individuals With Greater Than or Equal to 500/mm3 CD4+ T Cells and 200-400/mm3 CD4+ T Cells	Completed	Bristol-Myers Squibb	Phase 1	1969-12-31	To evaluate the safety and immunogenicity of HIV-1 MN rgp160 (Immuno-AG) in HIV-infected patients. To evaluate the immunogenicity of HIV-1 MN rgp160 immunogen by lymphocyte proliferation, specific antibody responses, and DTH reaction. To describe the durability of the immunogen in patients who respond to the first 7 injections when they are boosted every 8 weeks for an additional 6-12 months [AS PER AMENDMENT 11/12/96: stratum 1 patients only]. To describe the ability of the immunogen to induce a response after an additional 6-12 months of injections among patients who did not respond to the first 7 injections [AS PER AMENDMENT 11/12/96: stratum 1 patients only]. HIV-specific cellular immune responses appear to play an important role in HIV disease progression since both T helper and cytotoxic function against HIV decrease with disease progression.
NCT00000822 ↗	A Phase I/II Double-Blind Controlled Trial to Determine the Safety and Immunogenicity of HIV-1 MN rgp160 Immuno AG Vaccine Therapy in HIV-Infected Individuals With Greater Than or Equal to 500/mm3 CD4+ T Cells and 200-400/mm3 CD4+ T Cells	Completed	Immuno-US	Phase 1	1969-12-31	To evaluate the safety and immunogenicity of HIV-1 MN rgp160 (Immuno-AG) in HIV-infected patients. To evaluate the immunogenicity of HIV-1 MN rgp160 immunogen by lymphocyte proliferation, specific antibody responses, and DTH reaction. To describe the durability of the immunogen in patients who respond to the first 7 injections when they are boosted every 8 weeks for an additional 6-12 months [AS PER AMENDMENT 11/12/96: stratum 1 patients only]. To describe the ability of the immunogen to induce a response after an additional 6-12 months of injections among patients who did not respond to the first 7 injections [AS PER AMENDMENT 11/12/96: stratum 1 patients only]. HIV-specific cellular immune responses appear to play an important role in HIV disease progression since both T helper and cytotoxic function against HIV decrease with disease progression.
NCT00000822 ↗	A Phase I/II Double-Blind Controlled Trial to Determine the Safety and Immunogenicity of HIV-1 MN rgp160 Immuno AG Vaccine Therapy in HIV-Infected Individuals With Greater Than or Equal to 500/mm3 CD4+ T Cells and 200-400/mm3 CD4+ T Cells	Completed	National Institute of Allergy and Infectious Diseases (NIAID)	Phase 1	1969-12-31	To evaluate the safety and immunogenicity of HIV-1 MN rgp160 (Immuno-AG) in HIV-infected patients. To evaluate the immunogenicity of HIV-1 MN rgp160 immunogen by lymphocyte proliferation, specific antibody responses, and DTH reaction. To describe the durability of the immunogen in patients who respond to the first 7 injections when they are boosted every 8 weeks for an additional 6-12 months [AS PER AMENDMENT 11/12/96: stratum 1 patients only]. To describe the ability of the immunogen to induce a response after an additional 6-12 months of injections among patients who did not respond to the first 7 injections [AS PER AMENDMENT 11/12/96: stratum 1 patients only]. HIV-specific cellular immune responses appear to play an important role in HIV disease progression since both T helper and cytotoxic function against HIV decrease with disease progression.
NCT00000859 ↗	A Randomized Trial of the Efficacy and Safety of a Strategy of Starting With Nelfinavir Versus Ritonavir Added to Background Antiretroviral (AR) Nucleoside Therapy in HIV-Infected Individuals With CD4+ Cell Counts Less Than or Equal to 200/mm3	Completed	National Institute of Allergy and Infectious Diseases (NIAID)	N/A	1969-12-31	To compare nelfinavir (NFV) with ritonavir (RTV) for delaying disease progression or death in HIV-infected patients with CD4+ cell counts less than 100 cells/mm3 [AS PER AMENDMENT 3/11/98: less than or equal to 200 cells/mm3]. To compare NFV with RTV for the development of adverse events and for rates of permanent discontinuation of study medication. [AS PER AMENDMENT 10/02/97: To compare by intention-to-treat analysis for disease progression, including death, the following two regimens: NFV plus background combination antiretroviral (AR) therapy followed by indinavir (IDV) or RTV in the event of significant intolerance; and RTV plus AR therapy followed by IDV, then NFV, in the event of significant intolerance.] [AS PER AMENDMENT 3/11/98: SUBSTUDY CPCRA 045: To determine the relative rates of emergence of HIV-1 resistance and to compare changes in plasma HIV RNA levels and CD4+ cell counts in a sample of patients with CD4+ cell counts
NCT00000888 ↗	Safety and Effectiveness of Ritonavir Plus Lamivudine Plus Zidovudine in HIV-Infected Pregnant Women and Their Babies	Completed	Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)	Phase 1	1969-12-31	The purpose of this study is to see if it is safe and effective to give ritonavir (RTV) plus lamivudine (3TC) plus zidovudine (ZDV) to HIV-infected pregnant women during pregnancy and to their babies after birth. Pregnant women who are HIV-positive are at risk of giving HIV to their babies during pregnancy or delivery. It is important to learn how to prevent HIV-positive pregnant women from giving HIV to their babies. RTV and ZDV have been shown to be safe and effective against HIV in adults. The combination of 3 anti-HIV drugs (RTV, 3TC, and ZDV) may help prevent HIV infection from mother to infant but studies are needed to determine whether they are safe and effective during pregnancy.

Clinical Trial Conditions for RITONAVIR

Condition Name

Condition Name for RITONAVIR
Intervention	Trials
HIV Infections	350
HIV	84
HIV Infection	71
Healthy	66

Condition MeSH

Condition MeSH for RITONAVIR
Intervention	Trials
HIV Infections	495
Acquired Immunodeficiency Syndrome	129
Infections	122
Hepatitis C	110

Clinical Trial Locations for RITONAVIR

Trials by Country

Trials by Country for RITONAVIR
Location	Trials
Canada	214
Spain	210
Brazil	94
Australia	81
Mexico	79

Trials by US State

Trials by US State for RITONAVIR
Location	Trials
California	227
New York	190
Florida	174
Texas	160
Illinois	142

Clinical Trial Progress for RITONAVIR

Clinical Trial Phase

Clinical Trial Phase for RITONAVIR
Clinical Trial Phase	Trials
PHASE4	1
PHASE3	1
PHASE2	3

Clinical Trial Status

Clinical Trial Status for RITONAVIR
Clinical Trial Phase	Trials
Completed	722
Terminated	75
Recruiting	72

Clinical Trial Sponsors for RITONAVIR

Sponsor Name

Sponsor Name for RITONAVIR
Sponsor	Trials
National Institute of Allergy and Infectious Diseases (NIAID)	112
Abbott	71
Boehringer Ingelheim	70

Sponsor Type

Sponsor Type for RITONAVIR
Sponsor	Trials
Other	897
Industry	711
NIH	182

Ritonavir clinical trials update, market analysis, and exclusivity timeline: what to expect for pipeline, generics, and revenues

Last updated: July 27, 2026

Ritonavir is an antiretroviral protease inhibitor in systemic use for HIV-1 therapy and, historically, as a pharmacokinetic booster. As a mature, off-patent small molecule in most major markets, near-term growth is primarily driven by (1) steady demand in combination regimens, (2) distribution and guideline positioning, and (3) any incremental lifecycle value from new formulations or trial-driven expanded use. Active development is largely incremental and concentrated in new combinations, dose/fixed-dose opportunities, or drug-drug interaction (DDI) characterization rather than first-in-class breakthrough studies.

---

Ritonavir clinical trials update: what studies are active and what endpoints matter now?

Direct answer: Current ritonavir trial activity in 2024-2026 is mainly aimed at combination regimens, formulation/PK work, or pharmacology studies supporting clinical use and regulatory alignment, with limited evidence of large phase 3 new-drug programs.

Which ritonavir clinical trial types dominate

1. PK and bioequivalence: assessments of exposure, food effects, and interaction profiles to support dosing in special populations.
2. Combination therapy evaluation: ritonavir used as a booster in multi-drug HIV regimens.
3. Formulation refinement: changes in dosage form, pediatric suitability, or tolerability-focused adjustments.
4. Real-world evidence or comparative effectiveness: studies comparing ritonavir-containing regimens versus other boosted protease inhibitor strategies.

What endpoints are used

• PK endpoints: Cmax, AUC, trough (Cmin), and sometimes population PK model fit.
• Virologic endpoints (HIV): HIV-1 RNA suppression, time to virologic failure, and resistance emergence.
• Safety endpoints: hepatotoxicity signals, gastrointestinal tolerability, metabolic changes, and adverse event rate comparisons.
• DDI endpoints: alterations in exposure for co-administered agents to support labeling and prescribing.

What to watch in the next read-through

• Any trial that changes labeling language around pediatric dosing, boosted regimens, or interaction constraints can move prescribing volume.
• Any trial that supports new formulations with improved adherence can shift channel mix even if active ingredient demand is steady.

---

Are there any ritonavir phase 3 trials right now?

Direct answer: No clear, widely reported phase 3 “new molecule” ritonavir program is the dominant driver. Trial activity that impacts market access is more likely phase 1/2 PK, bioequivalence, and combination regimen work rather than registrational phase 3 for a standalone indication.

Why phase 3 registrational programs are rare for ritonavir

• Ritonavir’s role is established and often used as a pharmacologic booster.
• Competitive classes (integrase inhibitors, other boosters) reduce the need for large outcome trials unless a regulatory label expansion is targeted.

---

Ritonavir market analysis: who buys it, how is it priced, and what demand is durable?

Direct answer: Ritonavir demand is structurally tied to HIV treatment guidelines and the availability of boosted protease inhibitor options. Revenues are supported by ongoing prescribing and supply continuity, but pricing power is constrained by generics and competition.

Market structure

• Global demand is concentrated in HIV programs where protease inhibitor-based or booster-based regimens are used for:
  • patients with resistance patterns,
  • tolerability constraints,
  • specific guideline pathways or regimen availability.
• Channel mix depends on country procurement and national formularies.
• Competitive set includes other ritonavir-boosted protease inhibitors and alternative booster strategies.

Pricing and reimbursement dynamics

• In most geographies, ritonavir is in the generic era, compressing manufacturer margins.
• Market value is influenced by:
  • public sector procurement contracts,
  • tender cycles,
  • distribution partnerships,
  • intermittent supply disruptions that can temporarily lift realized price.

Ritonavir as a booster vs. standalone

• The economics depend on whether ritonavir is:
  • co-formulated with another active,
  • prescribed as a stand-alone booster with partner agents,
  • supplied via fixed-dose combinations that reduce ritonavir unit consumption.

---

Ritonavir exclusivity and patent estate: when does exclusivity end and when can generics launch?

Direct answer: Ritonavir is an established product with expired primary patents in most markets; remaining exclusivity typically arises from secondary patents (formulations, processes, specific combinations) or regulatory exclusivities tied to specific product approvals.

How to think about “exclusivity” for ritonavir in 2026

• Originator patents for the active ingredient date back to the initial protease inhibitor era and are generally long expired.
• “Exclusivity” in practice is more about:
  • last standing secondary IP (process, polymorph, formulation, specific method-of-use),
  • pediatric use protections if applicable for a specific NDA or formulation,
  • any jurisdiction-specific data exclusivity tied to specific filings.

What this means for competitive risk

• The generic launch risk for ritonavir as a molecule is generally already realized.
• The remaining risk is targeted: competitors can enter if they do not infringe any remaining secondary patents on the specific product strength/formulation/process.

---

What patents protect ritonavir in the US and Europe?

Direct answer: Patent protection for ritonavir today typically resides in secondary IP around formulations, manufacturing processes, and specific labeled uses rather than composition-of-matter for the core drug substance.

Where patent protection tends to concentrate

• Formulation patents: specific dosage forms, excipient systems, bioavailability enhancements.
• Manufacturing process patents: steps controlling impurity profile, yield, or crystallization.
• Method-of-use patents: dosing schedules or clinical use contexts, including boosting regimens.
• Packaging and stability: less common but still present for certain product presentations.

How this impacts diligence

• Licensing and litigation risk is evaluated at the product presentation level (strength, dosage form, and manufacturer filing) not at the molecule level.

---

What is the Orange Book status of ritonavir?

Direct answer: Ritonavir is generally represented in the FDA system through historical listings and multiple generic versions; the key diligence step is identifying which listings correspond to the specific dosage form/strength and whether any patents are listed that still appear enforceable.

Orange Book diligence checklist for ritonavir

• Identify active FDA product entries for each dosage form and strength.
• Map listed patents to:
  • composition/formulation,
  • method-of-use,
  • process/manufacturing.
• Identify patent status lines:
  • expiration date,
  • listed vs. withdrawn patents,
  • any current litigation stay or court status if publicly available.

---

Paragraph IV challenges for ritonavir: how often do they happen and what outcomes matter?

Direct answer: For a mature molecule like ritonavir, Paragraph IV activity is generally intermittent and more likely tied to remaining secondary patents for specific product presentations.

Why Paragraph IV is less common here

• Most opportunities are already exploited by generic entrants.
• Remaining patents are often formulation/process-specific and limited to certain strengths or product presentations.

What to track

• Any new challenge signals remaining enforcement value and can affect settlement timing and generic market share.

---

What patent litigation affects ritonavir generics or biosimilar competition?

Direct answer: Ritonavir is not a biologic, so biosimilar frameworks do not apply. Litigation, where it occurs, is typically generic-vs-brand or generic-vs-secondary-patent disputes for product presentations.

Litigation categories

• Infringement claims against ANDA filers for listed formulation/process patents.
• Validity/unenforceability disputes focused on obviousness, anticipation, and written description.
• Settlement agreements controlling market entry dates.

---

Market projection for ritonavir (2026-2031): revenue growth drivers and downside risks

Direct answer: Ritonavir’s revenue trajectory is more likely to be flat-to-low growth globally, with country-level volatility driven by procurement, tender pricing, and competitive substitutions within HIV regimens.

Base-case growth logic

• Demand persistence: protease inhibitor-based regimens remain options where resistance or clinical constraints apply.
• Supply continuity: multiple manufacturers and supply resilience reduce major demand shocks.
• Limited lifecycle expansion: absent major new indications, growth relies on incremental label refinements or formulation improvements.

Upside scenarios

• Any new labeling expansion that increases usage in specific populations.
• Improved pediatric acceptability or tolerability enabling incremental uptake.
• Favorable guideline positioning compared with alternative boosters.

Downside scenarios

• Continued guideline shift toward other classes reduces the long-tail need for boosted protease inhibitor strategies.
• Price compression from additional generic entrants or intensified tender competition.
• Regulatory or manufacturing quality issues impacting supply.

---

How does ritonavir compare with other HIV protease inhibitors and boosters?

Direct answer: Ritonavir’s clinical role as a booster keeps baseline demand, but newer regimens built around non-protease inhibitor backbones reduce structural growth.

Comparative market positioning

• Other boosted protease inhibitors compete for regimen share.
• Integrase inhibitor-driven standards of care reduce the need for protease inhibitor backbones in newly treated patients.
• Ritonavir’s sustained use is strongest in:
  • specific resistance profiles,
  • tolerability-driven sequencing,
  • situations where boosted protease inhibitors remain clinically indicated.

---

What formulations are protected for ritonavir and how do they affect generic entry?

Direct answer: Generic entry risk depends on whether any enforceable patents remain for specific formulations, excipient systems, or manufacturing processes that match the ANDA product design.

Formulation-specific barriers

• Patents that claim:
  • dissolution profile improvements,
  • stability improvements that affect shelf life,
  • impurity control processes.
• If a generic can design around claims (different process/formulation), market entry can proceed even if active ingredient entry is already present.

---

Commercial landscape: which companies produce ritonavir and how concentrated is supply?

Direct answer: Supply is typically fragmented across generic manufacturers in most regions, with concentration varying by tender market and product presentation.

What to look for in producer lists

• Strength and dosage form: tablet vs. liquid formulation impacts bidder participation.
• Country-specific tender eligibility and local quality certifications.
• Contract manufacturing and distribution arrangements.

(No company-level manufacturer and listing-level data is provided in the prompt, so no reliable producer table can be generated without introducing unverifiable specifics.)

---

Key takeaways

• Ritonavir’s near-term clinical and market trajectory is driven by incremental formulation/PK/combination studies rather than registrational phase 3 programs.
• Revenue is structurally constrained by generic competition; growth is most sensitive to procurement dynamics and any label expansion that changes guideline usage.
• The remaining patent risk is concentrated in secondary formulation, process, and method-of-use patents tied to specific product presentations, not composition-of-matter.

---

FAQs

1. Does ritonavir still have an active clinical development pipeline in HIV beyond pharmacokinetic studies?
Trial activity centers on PK, DDI, and regimen optimization rather than new registrational programs.

2. What is the main reason ritonavir demand stays stable despite generic competition?
Guideline and clinical utility as a booster in selected HIV populations supports persistent baseline prescribing.

3. Can new ritonavir formulations delay generic entry?
Yes, if enforceable secondary patents cover formulation or manufacturing approaches specific to a dosage form/strength.

4. How do drug-drug interaction results affect ritonavir labeling and market use?
Updated DDI data can tighten or expand co-administration guidance, influencing prescriber behavior and regimen selection.

5. Is biosimilar competition relevant for ritonavir?
No. Ritonavir is a small molecule; competition is from generic ANDAs and, where applicable, product-presentation lifecycle changes.

---

References (APA)

No sources were provided in the prompt, and no reliable, citable dataset (FDA Orange Book entries, ClinicalTrials.gov trial lists, or company/regulatory filings) is included in the input.